Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases

Table 1 Clinicopathologic features of the patients

Clinicopathologic features	TACEn = 22 (%)	Controln = 38 (%)	Statistical test	P value
Sex			χ2 = 0.310	0.578
Male	16 (72.7)	29 (76.3)
Female	6 (27.3)	9 (23.7)
Age (yr)	53.0 (49.3-59.6)	55.0 (48.0-62.0)	U = 5.000	0.279
ECOG PS			χ2 = 2.344	0.126
0-1	16 (72.7)	20 (52.6)
2	6 (27.3)	18 (47.4)
Primary location			χ2 = 0.012	0.994
Stomach	9 (40.9)	15 (39.5)
Small intestinal	9 (40.9)	16 (42.1)
Other	4 (18.2)	7 (18.4)
Number of liver lesions			χ2 = 1.805	0.406
1	8 (36.4)	8 (21.1)
2-5	9 (40.9)	20 (52.6)
> 5	5 (22.7)	10 (26.3)
Extrahepatic metastases			χ2 = 0.083	0.773
Yes	9 (40.9)	17 (44.7)
No	13 (59.1)	21 (55.3)
Sunitinib second-line therapy before TACE			χ2 = 0.992	0.319
Yes	11 (50.0)	24 (63.2)
No	11 (50.0)	14 (36.8)
TKI reintroduction			χ2 = 1.778	0.182
Yes	10 (45.5)	24 (63.2)
No	12 (54.5)	14 (36.8)

TACE: Transcatheter arterial chemoembolization; ECOG PS: The Eastern Cooperative Oncology Group performance status; TKI: Tyrosine kinase inhibitors.